Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEP07 in advanced or metastatic solid tumors
NCT05983523Phase 1Recruiting
- Sponsor
- PharmaEngine, Inc.
- Start
- Mar 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PEP07 in solid tumor, sponsored by PharmaEngine, Inc. Primary endpoints: Dose-Limited Toxicity at 4 weeks, Maximum Tolerated Dose at 4 weeks and 1 more. Started Mar 2024; status: recruiting.
02
Drugs
PEP07
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05983523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05983523.